한글목차

약제 요약

OPDIVO(Opdivo, 니볼루맙)는 인간 최초의 면역글로불린 G4(IgG4) PD-1 면역 체크포인트 억제 항체로서 PD-1 수용체와 그 리간드인 PD-L1과 PD-L2의 상호 작용을 억제하여 세포성 면역반응을 억제합니다. 표적 면역치료는 현재 종양 환자들에게 가장 유망한 치료법으로 떠오르고 있습니다. 활성화된 T세포에 발현된 PD-1은 면역 억제를 역전시켜 T세포의 활성화를 해제할 수 있습니다. 니볼루맙은 이미 확립된 약물로, 현재 다양한 적응증과 다양한 환자군에 대한 승인을 받았습니다.

현재 재발성 상피성 난소암을 대상으로 한 임상 2상 시험(NCT02873962)을 통해 이 약물을 평가했습니다.

주요 6 시장(미국·독일·프랑스·이탈리아·스페인·영국)에서 난소암용 OPDIVO에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 난소암에서의 OPDIVO 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 OPDIVO 시장 평가

• 난소암에서 OPDIVO의 시장 전망
• 주요 6시장 분석
  • 주요 6 시장 난소암용 OPDIVO의 시장 규모
• 시장 분석 : 국가별
  • 미국의 난소암용 OPDIVO의 시장 규모
  • 독일의 난소암용 OPDIVO의 시장 규모
  • 영국의 난소암용 OPDIVO의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"OPDIVO Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets. A detailed picture of the OPDIVO for ovarian cancer in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the OPDIVO for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OPDIVO market forecast analysis for ovarian cancer in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

OPDIVO (also known as Nivolumab) is the first-in-human immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response. Targeted immunotherapy has now become the most promising approach for tumor patients. PD-1 expressed on activated T-cells can reverse immune suppression and release T-cell activation. Nivolumab is an already established drug and is currently approved in different indications and for different patient segments.

Currently, the drug is being developed in a Phase II (NCT02873962) clinical study evaluating the drug in relapsed epithelial ovarian cancer.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the OPDIVO description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on OPDIVO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OPDIVO research and development activities in ovarian cancer across the United States and Europe.
• The report also covers the patents information with expiry timeline around OPDIVO.
• The report contains forecasted sales of OPDIVO for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for OPDIVO in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OPDIVO Analytical Perspective by DelveInsight

• In-depth OPDIVO Market Assessment

This report provides a detailed market assessment of OPDIVO for ovarian cancer in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.

• OPDIVO Clinical Assessment

The report provides the clinical trials information of OPDIVO for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OPDIVO dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to OPDIVO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OPDIVO in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of OPDIVO from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OPDIVO in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of OPDIVO?
• What is the clinical trial status of the study related to OPDIVO in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OPDIVO development?
• What are the key designations that have been granted to OPDIVO for ovarian cancer?
• What is the forecasted market scenario of OPDIVO for ovarian cancer?
• What are the forecasted sales of OPDIVO in the six major countries, including the United States, Europe (Germany, France, Italy, Spain), and the United Kingdom?
• What are the other emerging products available and how are these giving competition to OPDIVO for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. OPDIVO Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. OPDIVO Market Assessment

• 5.1. Market Outlook of OPDIVO in ovarian cancer
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of OPDIVO in the 6MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of OPDIVO in the United States for ovarian cancer
  • 5.3.2. Market Size of OPDIVO in Germany for ovarian cancer
  • 5.3.3. Market Size of OPDIVO in France for ovarian cancer
  • 5.3.4. Market Size of OPDIVO in Italy for ovarian cancer
  • 5.3.5. Market Size of OPDIVO in Spain for ovarian cancer
  • 5.3.6. Market Size of OPDIVO in the United Kingdom for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options